We seek to define the molecular mechanisms by which histone deacetylase 6 (HDAC6) and stress granules (SGs) interactively drive the pathophysiology of tauopathies, such as Frontotemporal Dementia. In so doing, we will test the hypothesis that loss of HDAC6 activity augments site-specific tau acetylation, preventing the pathological recruitment of tau to stress granules, and slowing disease progression. We recently reported that HDAC6-mediated deacetylation of tau enhances accumulation and aggregation, and we have now identified the acetylation sites on tau that are regulated by HDAC6. We also recently reported that tau pathology develops in concert with SG pathology in human and mouse models. Understanding the role of HDAC6 in regulating tau acquires added significance because HDAC6 regulates SGs, which are protein/RNA complexes that form in response to translational inhibition. Thus, HDAC6 functions as a nexus, linking acetylation of tau, SG formation and disease progression. The work in this proposal will elucidate the mechanisms by which HDAC6 regulates tau recruitment to SGs, with a particular focus on tau acetylation, and also assess whether decreasing HDAC6 expression with antisense oligonucleotides (ASOs) is sufficient to alleviate both tau and SG pathology. We have already identified ASOs targeting HDAC6 that effectively decrease expression in mouse primary neurons, and through an active collaboration with Isis Pharmaceuticals, are working to identify ASOs that will progress to in vivo testing. Given HDAC6 inhibition or knockout produces no obvious toxicity in cells or in mice, HDAC6 as a therapeutic target possesses strong translational appeal. Our proposal is structured to provide a greater understanding of the intricate and dynamic relationship between HDAC6 and tau, as well as elucidate the role of HDAC6 and tau acetylation in SG dynamics. We will generate acetyl tau antibodies on HDAC6-responsive sites to investigate how acetylation on these key sites affects tau biology and SG dynamics in our cell culture and rTg4510 mouse models as well as postmortem brain tissue from tauopathy cases (Aim 1). We will also determine whether modulation of HDAC6, through the use of ASOs, diminishes tauopathy and preserves cognition in vivo (Aim 2). Using mouse primary neurons, fibroblast-derived neurons from human tauopathy patients, which we show exhibit robust SG formation in response to stress, and rTg4510 mice treated with HDAC6 ASOs, we will further determine the roles of HDAC6, tau and acetylation in regulating stress granule dynamics (Aim 3). Completion of these studies in tandem will fundamentally expand our knowledge of the pathophysiology of tauopathies, and provide key insights into the pre-clinical efficacy of HDAC6 ASOs as a novel therapeutic strategy.

Public Health Relevance

We seek to understand how the enzyme histone deacetylase 6 (HDAC6) and stress granules, which are protein/RNA complexes, drive disease progression in dementia. We aim to therapeutically tamp down HDAC6 to modulate two competing cellular processes, acetylation and phosphorylation, at specific cellular sites on the tau protein, thereby decreasing the harmful aggregation of tau and the neuronal response to stress. We will test whether treatment with antisense oligonucleotides (ASOs) diminishes disease progression in cell models and preserves cognition in mouse models, thereby providing key insights into the pre-clinical efficacy of HDAC6 ASOs as a novel therapeutic strategy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS089544-01
Application #
8796020
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Sutherland, Margaret L
Project Start
2014-09-01
Project End
2019-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic Jacksonville
Department
Type
DUNS #
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Li, Dan; Wang, Lei; Maziuk, Brandon F et al. (2018) Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau. J Biol Chem 293:12081-12094
Eftekharzadeh, Bahareh; Daigle, J Gavin; Kapinos, Larisa E et al. (2018) Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron 99:925-940.e7
Ash, Peter E A; Stanford, Elizabeth A; Al Abdulatif, Ali et al. (2017) Dioxins and related environmental contaminants increase TDP-43 levels. Mol Neurodegener 12:35
Wiepert, Daniela A; Lowe, Val J; Knopman, David S et al. (2017) A robust biomarker of large-scale network failure in Alzheimer's disease. Alzheimers Dement (Amst) 6:152-161
Carlomagno, Yari; Chung, Dah-Eun Chloe; Yue, Mei et al. (2017) An acetylation-phosphorylation switch that regulates tau aggregation propensity and function. J Biol Chem 292:15277-15286
Jones, David T; Graff-Radford, Jonathan; Lowe, Val J et al. (2017) Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex 97:143-159
Russo, Arianna; Scardigli, Raffaella; La Regina, Federico et al. (2017) Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes. Hum Mol Genet 26:1407-1418
Zhou, Qingde; Yen, Allen; Rymarczyk, Grzegorz et al. (2016) Impairment of PARK14-dependent Ca(2+) signalling is a novel determinant of Parkinson's disease. Nat Commun 7:10332
Lowe, Val J; Curran, Geoffry; Fang, Ping et al. (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4:58
Vanderweyde, Tara; Apicco, Daniel J; Youmans-Kidder, Katherine et al. (2016) Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity. Cell Rep 15:1455-1466

Showing the most recent 10 out of 17 publications